Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × MK 2206 × CNS × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 6 Breast 5 Head & Neck 3 Thoracic 2 Gynecologic 2 Genitourinary 2 Sarcoma 1 Other hematologic neoplasm 1 NET 1 Lymphoid 1 Endocrine 1 Dermatologic 1 CNS 1

Conditions

Interventions

Temozolomide 231 Radiotherapy 131 Bevacizumab 128 Etoposide 59 Cyclophosphamide 59 Carboplatin 57 Magnetic Resonance Spectroscopy 53 Irinotecan 50 Cisplatin 39 pembrolizumab 38 Vincristine 36 Radiosurgery 34 Nivolumab 32 Filgrastim 31 Topotecan 28 sargramostim 27 Specimen Handling 27 Radiation 26 Doxorubicin 24 Lomustine 23 Erlotinib Hydrochloride 23 Carmustine 23 Isotretinoin 21 Chemotherapy, Adjuvant 21 Thiotepa 20 Peripheral Blood Stem Cell Transplantation 20 Granulocyte-Macrophage Colony-Stimulating Factor 20 Surgical Procedures, Operative 19 Melphalan 18 Ipilimumab 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01249105 2016-03-10

MK-2206 for Recurrent Malignant Glioma

Dana-Farber Cancer Institute

Phase 2 Withdrawn

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡